Literature DB >> 20054547

Acquired haemophilia caused by non-haemophilic factor VIII gene variants.

Andreas Tiede1, Roswith Eisert, Andreas Czwalinna, Wolfgang Miesbach, Inge Scharrer, Arnold Ganser.   

Abstract

The aetiology of anti-factor VIII (FVIII) autoantibody formation in acquired haemophilia remains unknown. We hypothesised that encounter of antigenically different, allogeneic FVIII may challenge inhibitor formation after presentation on MHC class II. Eighteen consecutive cases with acquired haemophilia were enrolled (nine females, nine males). A control group comprised 50 male and 50 female healthy blood donors. The coding region of the FVIII gene and the HLA-DRB1 genotype were studied. The presentation of foreign FVIII variants on the patient's MHC class II alleles was predicted using SYFPEITHI algorithm. A rare FVIII variant (E2004K) was found in one patient with acquired haemophilia after massive transfusion; the 2004 K allele was predicted to be presented on the patient's HLA-DRB1*0101. Moreover, distribution of a polymorphism (D1241E) was significantly skewed comparing patients and controls. Three of three patients with transfusion-associated disease carried 1241D in homozygous or hemizygous form and were predicted to present 1241E (foreign), but not 1241D (self), on their HLA-DRB1*0301. Therefore, encounter of 1241E may result in the presentation of a new T cell epitope in these patients. The same conditions were not found in any patient with acquired haemophilia of other causes. The expected frequency in the general Caucasoid population undergoing transfusion is 3% to 4%. In conclusion, encounter of variant allogeneic FVIII presented on a suitable MHC background could be a risk factor for inhibitor formation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20054547     DOI: 10.1007/s00277-009-0887-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

Review 1.  The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics.

Authors:  Zuben E Sauna; Jay N Lozier; Carol K Kasper; Chen Yanover; Timothy Nichols; Tom E Howard
Journal:  Blood       Date:  2014-11-18       Impact factor: 22.113

Review 2.  Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice.

Authors:  Allyson M Pishko; Bhavya S Doshi
Journal:  J Blood Med       Date:  2022-05-11

3.  Acquired haemophilia A after stem cell transplant for sickle cell disease: treatment with recombinant porcine factor VIII (OBI-1) and tolerance induction with rituximab/prednisone.

Authors:  J N Lozier; K Nghiem; M Lee; B Hodsdon; G Joe; R P Weitzel; J F Tisdale; M Hsieh
Journal:  Haemophilia       Date:  2014-03       Impact factor: 4.287

4.  Identification of a shared F8 mutation in the Korean patients with acquired hemophilia A.

Authors:  Sung Ho Hwang; Jeong A Lim; Hugh Chul Kim; Hyun Woo Lee; Hye Sun Kim
Journal:  Korean J Hematol       Date:  2011-03-15

5.  Acquired Factor XI Inhibitor Presenting as Spontaneous Bilateral Subdural Hematoma in an Elderly Patient.

Authors:  Natale Vazzana; Luca Scarti; Chiara Beltrame; Antonella Picchi; Gianni Taccetti; Alberto Fortini
Journal:  Case Rep Hematol       Date:  2014-11-06

6.  Acute airway compromise and coagulopathy: a rare presentation of acquired haemophilia A.

Authors:  William Byron Howden; Jonathan Kam; Nicholas Leith; Shashinder Singh
Journal:  BMJ Case Rep       Date:  2020-05-04

7.  Hemorrhagic pericardial effusion as the debut of acquired hemophilia in a chronic lymphocytic leukemia patient: A case report, and a review of acquired hemophilia A-related hematological malignancies.

Authors:  José María Bastida; María Teresa Cano-Mozo; Felix Lopez-Cadenas; Victor Eduardo Vallejo; Soraya Merchán; Cecilia Santos-Montón; David González-Calle; Javier Carrillo; Ana Africa Martín; Jose Angel Torres-Hernández; Marcos González; Francisco Martín-Herrero; Pedro Pabón; Jose Ramon González-Porras
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.